Latest news with #PrecisionMedicine
Yahoo
4 days ago
- Business
- Yahoo
Favorable Government Support Fuels Germany's Biotech Innovation and Commercialization: Market to Surpass USD 94 Billion by 2034 Led by QIAGEN, Thermo Fisher Scientific, Illumina and Roche
German Biotechnology Market Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Germany Biotechnology Market Report and Forecast 2025-2034" has been added to Germany biotechnology market was valued at USD 35.30 Billion in 2024, bolstered by robust public and private investment in biotech innovation, alongside significant R&D endeavors supported by established academic and research institutions. The market is expected to grow at a CAGR of 10.30% during 2025-2034, potentially reaching USD 94.09 Billion by 2034. Government initiatives and funding play a critical role in accelerating the development and commercialization of advanced biotechnological solutions, contributing to market expansion. This growth is also underpinned by strong infrastructure, substantial R&D capabilities, and a skilled workforce. The increasing adoption of precision medicine and biopharmaceuticals is anticipated to further drive market growth in the forecast period. Increasing Prevalence of Chronic Diseases The market's growth is heavily influenced by the rising incidence of chronic and degenerative diseases. According to WHO data from 2021, conditions such as ischemic heart disease, Alzheimer's disease, stroke, various cancers, COPD, and kidney disorders impose a significant health burden, intensifying demand for innovative diagnostics, targeted therapies, and precision medicine. This drives forward the biotechnology sector, bolstered by increased research and development investments from both public and private sectors. Germany Biotechnology Market Trends Key trends include rising investments and the advent of cutting-edge, sustainable technologies. Investment confidence continues to grow, evidenced by a 78% increase in funding for German biotech firms, reaching EUR 1.917 billion in 2024, according to BIO Deutschland and EY. This capital influx is set to enhance market growth and technological progress. Additionally, innovative, eco-friendly food technologies are driving demand. In March 2024, the launch of Kynda's zero-waste mycelium-based food product in Germany highlighted a move towards sustainable consumer solutions, anticipating an increase in the market's growth and the adoption of sustainable biotech products. Germany Biotechnology Market Segmentation The market analysis includes segments such as: Product Type: Instruments, Reagents, Software and Services, Others Technology: Nanobiotechnology, Tissue Engineering, DNA Sequencing, Cell-based Assays, Fermentation, PCR Technology, Chromatography, Others Application: Health, Food & Agriculture, Natural Resources & Environment, Industrial Processing, Bioinformatics, Others Germany Biotechnology Market Share: DNA Sequencing's Impact The biotechnology market in Germany is diversified across various technologies, with DNA sequencing anticipated to lead. Innovations like Merck's Aptegra platform, which integrates multiple assays into one, significantly reduce testing times and costs, driving DNA sequencing's important role in the market's future growth. Leading Players in the Germany Biotechnology Market The major market players include: QIAGEN N.V: Expanded its portfolio by acquiring Genoox, enhancing AI-driven genetic data interpretation for clinical decision-making. Thermo Fisher Scientific, Inc: Introduced sustainable centrifuges in Germany, boosting energy efficiency in bioprocessing. Illumina Inc: Partnered with to launch an extensive clinical multiomic dataset, propelling advancements in metabolic disease therapies. F. Hoffman-La Roche Ltd: Gained FDA clearance for a dual mRNA probe assay improving B-cell lymphoma diagnostics. Other key companies include Evotec SE, Bio-Rad Laboratories, Agilent Technologies, and BioNTech SE. Key Questions Answered What was the Germany biotechnology market value in 2024? What is the forecast for 2025-2034? What drives demand in the market? How has the market performed historically, and future expectations? What are the major trends and challenges? Which product, technology, and application segments are expected to dominate? Who are the key players? Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $35.3 Billion Forecasted Market Value (USD) by 2034 $94.09 Billion Compound Annual Growth Rate 10.3% Regions Covered Germany Key Topics Covered 1 Preface 1.1 Objectives of the Study 1.2 Key Assumptions 1.3 Report Coverage - Key Segmentation and Scope 1.4 Research Methodology 2 Executive Summary 3 Biotechnology Market Overview 3.1 Europe Biotechnology Market 3.2 Germany Biotechnology Market 4 Vendor Positioning Analysis 4.1 Key Vendors 4.2 Prospective Leaders 4.3 Niche Leaders 4.4 Disruptors 5 Germany Biotechnology Market Landscape 5.1 Germany Biotechnology Market: Developers Landscape 5.2 Germany Biotechnology Market: Product Landscape 6 Germany Biotechnology Market Dynamics 6.1 Market Drivers and Constraints 6.2 SWOT Analysis 6.3 PESTEL Analysis 6.4 Porter's Five Forces Model 6.5 Key Demand Indicators 6.6 Key Price Indicators 6.7 Industry Events, Initiatives, and Trends 6.8 Value Chain Analysis 7 Germany Biotechnology Market Segmentation (2018-2034) 7.1 By Product Type 7.2 By Technology 7.3 By Application 8 Regulatory Framework 9 Patent Analysis 10 Funding and Investment Analysis 11 Strategic Initiatives 12 Supplier Landscape 13 Germany Biotechnology Market - Distribution Model (Additional Insight) 14 Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment German Biotechnology Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Globe and Mail
14-07-2025
- Business
- Globe and Mail
Precision Diagnostics & Medicine Market worth $246.66 billion by 2029
"Key players in the Precision diagnostic market include F. Hoffman La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), and Guardant Health (US) among others and key players in precision medicine market include Merck Co, Inc. (US), Gilead Sciences (US), AstraZeneca (UK), Novartis AG (Switzerland), among others." Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029 The report " Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029", is expected to reach USD 246.66 billion by 2029 from USD 145.53 billion in 2024, growing at a CAGR of 11.1% Factors such as the increasing integration of AI and ML for the development of advanced precision diagnostics and therapeutic solutions supported by the rising collaboration and investment by major pharmaceutical companies for the development of precision medicine and biomarker discovery drive the growth of the market. Moreover, the increasing demand for direct-to-consumer testing owing to the growing awareness of patients towards their health and the convenience offered by these tests supports the adoption of precision diagnostics. Additionally, the expanding focus of pharmaceutical companies on the development of precision solutions for other diseases such as neurodegenerative disorders and autoimmune diseases and the integration of wearable technology to enhance healthcare offers growth opportunities for players operating in the precision medicine market. However, factors such as the high cost of precision healthcare and the challenges related to the integration and management of big data in precision solution development restrain the growth of the market. Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029"View detailed Table of Content here - The monoclonal antibodies segment accounted for the largest share of the Precision Medicine Market, by product, during the forecast period. Based on products, the precision medicine market is divided into inhibitor drugs, monoclonal antibodies, cell and gene therapy, antiviral and anti-retroviral drugs, and other therapeutic products. The large share of the monoclonal antibodies products segment can be attributed to the fact that a large number of the approved precision therapies are monoclonal antibodies. This large share of this segment is also supported by the ongoing approvals for monoclonal antibody drugs for various cancers and other diseases highlighting a focus of pharmaceutical companies on the development of monoclonal antibodies as precision medicines. The oncology subsegment accounted for the largest share of the precision diagnostics market's indication segment in 2023 Based on indication, the precision diagnostics market is segmented into oncology, neurology, immunology, and other indications. The oncology segment accounted for the largest share of the precision diagnostics market by indication in 2023. The large share of this segment is attributed to the increase in cancer cases globally, supported by rising demand for diagnostic tests offering early and accurate cancer diagnosis. For this reason, life science companies are increasingly investing and collaborating to develop advanced oncology diagnostic tests. This dominance is expected to continue throughout the forecast period as major players are developing new technologies for better oncology diagnosis. Asia Pacific is registered as the fastest-growing region of the Precision diagnostics market in 2023. The Precision medicine market is divided into five regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America held the largest share of the precision diagnostics market, followed by Europe. Aisa Pacific registered the highest CAGR growth within the precision diagnostics market during the forecast period. The expansion of key diagnostic players in the region followed by favorable policies supporting the larger adoption of precision medicine is a supporting factor. Additionally, there is a greater awareness about personalized approach to treatments in these developed regions compared to the developing/ emerging economies. Key players in the Precision diagnostic market include F. Hoffman La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), and Guardant Health (US) among others and key players in precision medicine market include Merck Co, Inc. (US), Gilead Sciences (US), AstraZeneca (UK), Novartis AG (Switzerland), among others. Don't miss out on business opportunities in Precision Diagnostics & Medicine Market. Speak to our analyst and gain crucial industry insights that will help your business grow.
Yahoo
14-07-2025
- Business
- Yahoo
Compounding Pharmacies Market to Hit USD 19.9 Billion by 2032 Due to Rising Demand for Personalized Medications and Specialty Drug Shortages
U.S. Market Set to Reach USD 4.84 Billion by 2032, Fueled by the Surge in Tailored Prescriptions and Favorable Regulatory Support. Austin, July 14, 2025 (GLOBE NEWSWIRE) -- Compounding Pharmacies Market Size & Growth Analysis: According to SNS Insider, the global Compounding Pharmacies Market is witnessing a significant transformation, projected to grow from USD 12.6 billion in 2023 to USD 19.9 billion by 2032, expanding at a CAGR of 5.2%. In the United States, the market is advancing from USD 2.74 billion in 2024 to an anticipated USD 4.84 billion by 2032, driven by the accelerating demand for personalized medicine, evolving healthcare preferences, and supportive regulatory a Sample Report of Compounding Pharmacies Market@ Compounding pharmacies have become an essential bridge between standard pharmaceutical care and customized patient needs. As healthcare systems globally pivot toward precision medicine, the ability to tailor drugs—ranging from dosage adjustments to allergen-free and unique delivery formulations—is no longer a niche requirement but a central component of modern care. The Personalized Medicine Boom As chronic illnesses proliferate and patient populations become more diverse in their healthcare needs, standardized medications are often inadequate or unsuitable. Compounding pharmacies offer solutions for patients with drug allergies, pediatric needs, geriatric sensitivities, or non-traditional dosage requirements. This patient-first model is reshaping how physicians prescribe medications, especially in fields like pain management, hormone replacement therapy (HRT), veterinary care, and oncology. In particular, the U.S. market is showing robust momentum due to the widespread adoption of personalized prescriptions, growth in aging demographics, and a favorable outlook from oversight bodies such as the FDA and Pharmacy Compounding Accreditation Board (PCAB). Recent regulatory clarity has supported the expansion of both 503A and 503B outsourcing facilities, bolstering patient safety and quality assurance. Segment Analysis By Therapeutic Area: The pain management segment was the highest contributor to the therapeutic area category in 2023, and accounted for 35.1% of the total revenue share. Non-opioid alternatives and patient-specific formulations for chronic and acute pain will continue to fuel this space. Compared with patients individually, physicians prefer ways to make doses and reduce side effects. By Age Cohort: The adult category was the largest segment in 2023, with a share of 45.1%. Adults have needs for medication for which a drug must be reconstituted for allergies, lack of ability to swallow, or the need for a different dosage while this population segment is an important market demographic. By Sterility: Sterile compounded medications were the leading segment in 2023 with an overall market share of 60.52% and demand from ophthalmology and parenteral nutrition, and intrathecal therapies, etc. These drugs must have restrictive manufacturing procedures and are typically used in the hospital, surgery center, and oncology setting. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Regional Analysis The Asia Pacific was the largest compounding pharmacies market, accounting for the revenue share of over 40.4% in 2023, owing to increasing population requirements, high healthcare infrastructure, and growing personalized drug demands in China, Japan and India among others. A growing number of specialty clinics and locally developed pharmacy solutions were other factors that led the region to dominance. Europe is anticipated to grow at a CAGR based on revenue of 7.5% during the course of the forecast period 2024 to 2032 on account of rising usage of compounded drugs for pediatric and geriatric care. The European compounding pharmacy industry is projected to witness growing regulatory backing and increased pharmacy networks extended throughout Germany, France and the UK in the years to come. Major Players Analysis Listed in this Report are: Walgreen Co. Fagron Albertsons Companies The London Specialist Pharmacy Ltd Galenic Laboratories Limited Aurora Compounding MEDS Pharmacy Apollo Clinical Pharmacy Formul8 Fusion Apothecary and other players. Compounding Pharmacies Market Segmentation By Therapeutic Area Hormone Replacement Therapy Pain Management Specialty Drugs Dermatology Nutritional Supplements Others By Age Cohort Pediatric Adult Geriatric By Compounding Type Pharmaceutical Ingredient Alteration (PIA) Currently Unavailable Pharmaceutical Manufacturing (CUPM) Pharmaceutical Dosage Alteration (PDA) Others By Sterility Sterile Non-sterile Recent Developments Avita Pharmacy (2024): Created a strategic alliance with a research leader to pioneer advanced personalized compounding formulations. Medisca (2023): Released patient-focused formulations for compliance and taste preferences, such as pediatric and geriatric formulations. Fagron (February 2024): launched a series of hormone therapy compounding kits designed to help make pharmacies more efficient while also decreasing dosage variability. Compounding Pharmacies Market Report Scope Report Attributes Details Market Size in 2023 US$ 12.6 billion Market Size by 2032 US$ 19.9 billion CAGR CAGR of 5.2% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Buy a Single-User PDF of Compounding Pharmacies Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence (2023) 5.2 Prescription Trends, (2023), by Region 5.3 Drug Volume, by Region (2020-2032) 5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients. 6. Competitive Landscape 7. Compounding Pharmacies Market by Therapeutic Area 8. Compounding Pharmacies Market by Age Cohort 9. Compounding Pharmacies Market by Compounding Type 10. Compounding Pharmacies Market by Sterility 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion Related Reports Hormone Replacement Therapy Market Report 2024–2032 Personalized Medicine Market Size & Growth Forecast Pain Management Market Analysis About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-07-2025
- Business
- Yahoo
Aqtual secures $31m to commercialise rheumatoid arthritis test
Precision medicine company Aqtual has secured $31m in a Series B financing round to progress its active chromatin cell-free DNA (cfDNA) platform and launch a rheumatoid arthritis (RA) therapy response prediction test. The round saw participation from new investors Bold Capital and Bold Longevity Growth Fund, alongside previous investors Manta Ray Ventures, Genoa Ventures and Yu Galaxy. A strategic investor from the diagnostics sector also contributed, bolstering Aqtual's commercialisation efforts. In the PRIMA-102 prospective observational trial, the company has already enrolled 1,300 participants, aiming to validate the cfDNA-based blood test for RA patients. The study's completion is projected for the fourth quarter of this year. Subjects in the PRIMA-102 trial will be monitored through screening and baseline visits before the initiation of new biological disease-modifying antirheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) therapy. The trial aims to evaluate the test utilising genetic, transcriptomic, and/or epigenetic data to help clinicians predict the best treatment alternatives for RA subjects. At 12-week follow-ups, the trial will measure treatment response and disease activity, with blood samples and clinical outcome assessments taken at baseline and the 12-week mark. The company noted that in the US, RA is a significant health concern, contributing more than $19bn every year in direct healthcare expenses. Aqtual CEO and co-founder Diana Abdueva said: 'This raise marks a key inflection point for cfDNA diagnostics—not just for Aqtual, but for the broader field. 'Our platform uniquely captures the biology of chronic disease, enabling deeper insights to support more effective treatment planning strategies. "With this funding, strengthened by backing from a strategic partner, we're positioned to advance our internal pipeline and forge new partnerships that extend the impact of our platform across disease areas.' "Aqtual secures $31m to commercialise rheumatoid arthritis test" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
15-04-2025
- Health
- Associated Press
CVD researcher/clinician named Editor-in-Chief of Circulation: Genomic and Precision Medicine
( NewMediaWire ) - April 15, 2025 - DALLAS — Ferhaan Ahmad, M.D., Ph.D., FAHA, is the new editor-in-chief of Circulation: Genomic and Precision Medicine, a peer-reviewed scientific journal published by the American Heart Association, effective with the journal's April issue, published today. Ahmad is the founding director of the Cardiovascular Genomics Program and associate professor of internal medicine-cardiovascular medicine at the University of Iowa Carver College of Medicine in Iowa City, Iowa. He takes the helm leading Circulation: Genomic and Precision Medicine from Kiran Musunuru, M.D., Ph.D., M.P.H, FAHA, who served as interim editor-in-chief since April 2024. 'Dr. Ahmad's extensive cardiology expertise and leadership in the field of cardiovascular genomics, his commitment to innovation and drive for scientific advances will guide Circulation: Genomic and Precision Medicine to new heights as the specialty continues to evolve,' said Eldrin F. Lewis, M.D., M.P.H., FAHA, volunteer chair of the American Heart Association's Scientific Publishing Committee, which oversees the Association's 14 peer-reviewed scientific journals. Lewis is the Simon H. Stertzer, M.D., Professor of Cardiovascular Medicine and chief of the division of cardiovascular medicine at Stanford University in Stanford, California. Ahmad most recently served as an associate editor and senior associate editor of the Journal of the American Heart Association (JAHA) for the past 10 years. He stepped down from JAHA to assume his new role with Circulation: Genomic and Precision Medicine. 'Thank you to Dr. Ahmad for his integral role in advancing JAHA's impact and reputation for scientific excellence over the last decade,' said Lewis. Ahmad's additional roles at the University of Iowa include associate professor of molecular physiology and biophysics, associate professor of radiology and director of the Cardiovascular Disease Fellowship Training Program. He also leads a laboratory conducting basic and translational research into the genetic and genomic mechanisms underlying inherited cardiovascular disorders, including hypertrophic cardiomyopathy, dilated cardiomyopathy, glycogen storage cardiomyopathy, inherited arrhythmias and pulmonary hypertension, and the mechanisms by which the SGLT1 protein contributes to heritable and acquired heart failure. Ahmad's clinical expertise includes coronary artery disease, cardiomyopathy and other inherited cardiovascular conditions, and he continues to mentor countless postdoctoral fellows and medical, graduate and undergraduate students. 'Cardiovascular genetics combined with genomics is a quickly evolving field that is highly dependent on the contributions of many professionals from various disciplines, and advances are emerging quickly,' said Ahmad. 'In my new role as editor-in-chief, I am excited to build on the journal's success while elevating the inclusion of studies that advance implementation science, community-engaged/community-based participatory research, as well as papers highlighting equitable health and social drivers of health. These are critical areas to understanding the genetic and genomic basis of cardiovascular and cerebrovascular disease. Translating these findings to practice is key to improving care and outcomes for patients,' said Ahmad. Ahmad also plans to champion initiatives that strengthen the journal's position within the specialty, such as: Ahmad earned his doctor of medicine degree at McGill University in Montreal, Canada, followed by postgraduate clinical training at McGill University, Baylor College of Medicine in Houston and the Brigham and Women's Hospital in Boston. He subsequently earned a Ph.D. in human genetics from Baylor College of Medicine and completed a Howard Hughes Medical Institute postdoctoral fellowship in mouse genetics at Harvard Medical School. In addition to his role with JAHA, Ahmad has served in several leadership roles in the American Heart Association's Council on Genomic and Precision Medicine, the Council on Epidemiology and Prevention, and the Committee for Scientific Sessions Programming. He also serves on the Association's Hypertrophic Cardiomyopathy Science Advisory Group. Ahmad has received numerous research grants and is active in several clinical trials of novel therapies for heritable cardiomyopathies. He has co-authored more than 60 published, peer-reviewed research articles including serving as the chair of the writing group for the 2019 American Heart Association Scientific Statement, " Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards.' He also authored the chapter on cardiovascular genetics in the American College of Cardiology Self-Assessment Program (ACCSAP). Circulation: Genomic and Precision Medicine, which launched in 2008, is the leading scientific journal for original research detailing mechanistic, diagnostic, prognostic and therapeutic advances in genetics and genomics, including studies in human subjects, laboratory animals, in vitro and in silico, focused on relevance to human cardiovascular biology and disease. Areas of interest include investigations of clinical genetics as applied to cardiovascular disorders, the molecular basis of complex cardiovascular disorders, and novel applications of precision medicine. The online-only journal publishes six issues per year, and accepted articles are published online ahead of issue. Circulation: Genomic and Precision Medicine is part of the American Heart Association's portfolio of 14 peer-reviewed scientific journals: Circulation; Stroke; Hypertension; Journal of the American Heart Association; Arteriosclerosis, Thrombosis, and Vascular Biology; Circulation Research; Circulation: Arrhythmia and Electrophysiology; Circulation: Heart Failure; Circulation: Cardiovascular Imaging; Circulation: Cardiovascular Interventions; Circulation: Cardiovascular Quality and Outcomes; Stroke: Vascular and Interventional Neurology; and Annals of Internal Medicine: Clinical Cases. Each journal is editorially independent of one another and the Association in support of open dialogue and discourse, which are essential to the dynamic nature of scientific discovery. Editors-in-chief are selected by the Association's volunteer-led Scientific Publishing Committee, and each editor-in-chief assembles and manages the editorial board, vision and strategy for their journal. The Association is the publisher of the journals; however, the Association has no oversight on the science content published. Studies published in the American Heart Association's scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content. Overall financial information is available here. Additional Resources: ### About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy and care, we work tirelessly to advance health and transform lives every day. Connect with us on Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries: 214-706-1173 Michelle Kirkwood: [email protected] For Public Inquiries: 1-800-AHA-USA1 (242-8721) and
